David Badawi Sells 3,167 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 3,167 shares of the business’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.99, for a total transaction of $18,970.33. Following the transaction, the chief technology officer now directly owns 1,756,481 shares of the company’s stock, valued at approximately $10,521,321.19. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Sight Sciences Trading Down 3.2 %

SGHT stock opened at $5.81 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 11.01 and a quick ratio of 10.50. The stock has a market capitalization of $289.08 million, a price-to-earnings ratio of -5.19 and a beta of 2.71. The business has a fifty day moving average price of $6.50 and a 200 day moving average price of $6.23. Sight Sciences, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $8.45.

Sight Sciences (NASDAQ:SGHT) last announced its earnings results on Thursday, August 1st. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.06. Sight Sciences had a negative net margin of 65.90% and a negative return on equity of 45.68%. The company had revenue of $21.37 million during the quarter, compared to the consensus estimate of $21.32 million. During the same period in the previous year, the firm posted ($0.30) earnings per share. Analysts expect that Sight Sciences, Inc. will post -1 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on SGHT. Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a research report on Friday, August 2nd. Citigroup increased their price objective on shares of Sight Sciences from $6.00 to $6.50 and gave the company a “neutral” rating in a research note on Wednesday, July 10th. Lake Street Capital initiated coverage on Sight Sciences in a report on Wednesday, August 21st. They set a “buy” rating and a $10.00 price objective on the stock. Finally, Morgan Stanley raised their target price on Sight Sciences from $5.40 to $6.50 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, Sight Sciences presently has an average rating of “Hold” and an average target price of $7.25.

Institutional Investors Weigh In On Sight Sciences

Institutional investors and hedge funds have recently modified their holdings of the business. RTW Investments LP acquired a new stake in shares of Sight Sciences during the fourth quarter worth $850,000. Jacobs Levy Equity Management Inc. increased its position in shares of Sight Sciences by 25.5% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 377,057 shares of the company’s stock valued at $1,991,000 after buying an additional 76,549 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Sight Sciences by 51.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,653 shares of the company’s stock worth $141,000 after buying an additional 9,106 shares during the period. Vanguard Group Inc. grew its stake in Sight Sciences by 5.5% in the first quarter. Vanguard Group Inc. now owns 1,556,450 shares of the company’s stock valued at $8,218,000 after acquiring an additional 81,768 shares during the period. Finally, Acadian Asset Management LLC raised its holdings in Sight Sciences by 256.6% during the 2nd quarter. Acadian Asset Management LLC now owns 83,693 shares of the company’s stock worth $556,000 after buying an additional 60,220 shares during the period. 55.51% of the stock is owned by institutional investors.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.